These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385 [TBL] [Abstract][Full Text] [Related]
6. Serum metabolomic characterization of PLA2G6-associated dystonia-parkinsonism: A case-control biomarker study. Chen C; Lou MM; Sun YM; Luo F; Liu FT; Luo SS; Wang WY; Wang J Front Neurosci; 2022; 16():879548. PubMed ID: 36033628 [TBL] [Abstract][Full Text] [Related]
7. Clinical Sphingolipids Pathway in Parkinson's Disease: From GCase to Integrated-Biomarker Discovery. Esfandiary A; Finkelstein DI; Voelcker NH; Rudd D Cells; 2022 Apr; 11(8):. PubMed ID: 35456032 [TBL] [Abstract][Full Text] [Related]
8. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
9. A preliminary data: Evaluation of serum Galectin-3 levels in patients with Idiopathic Parkinson's Disease. Yazar HO; Yazar T; Cihan M J Clin Neurosci; 2019 Dec; 70():164-168. PubMed ID: 31471077 [TBL] [Abstract][Full Text] [Related]
10. Using 'swallow-tail' sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson's disease: A susceptibility-weighted imaging study. Wang N; Yang H; Li C; Fan G; Luo X Eur Radiol; 2017 Aug; 27(8):3174-3180. PubMed ID: 28105503 [TBL] [Abstract][Full Text] [Related]
11. CEST 2022-three-dimensional amide proton transfer (APT) imaging can identify the changes of cerebral cortex in Parkinson's disease. Tian Y; Li X; Wang X; Su W; Li S; Wang W; Zhang Y; Li C; Chen M Magn Reson Imaging; 2023 Oct; 102():235-241. PubMed ID: 37356600 [TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls. Goldknopf IL; Park HR; Sabbagh M Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864 [TBL] [Abstract][Full Text] [Related]
14. Fasting serum α‑hydroxybutyrate and pyroglutamic acid as important metabolites for detecting isolated post-challenge diabetes based on organic acid profiles. Chou J; Liu R; Yu J; Liu X; Zhao X; Li Y; Liu L; Sun C J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():6-16. PubMed ID: 30267980 [TBL] [Abstract][Full Text] [Related]
15. Radiomic Features of the Nigrosome-1 Region of the Substantia Nigra: Using Quantitative Susceptibility Mapping to Assist the Diagnosis of Idiopathic Parkinson's Disease. Cheng Z; Zhang J; He N; Li Y; Wen Y; Xu H; Tang R; Jin Z; Haacke EM; Yan F; Qian D Front Aging Neurosci; 2019; 11():167. PubMed ID: 31379555 [No Abstract] [Full Text] [Related]
16. Potential Tear Biomarkers for the Diagnosis of Parkinson's Disease-A Pilot Study. Acera A; Gómez-Esteban JC; Murueta-Goyena A; Galdos M; Azkargorta M; Elortza F; Ruzafa N; Ibarrondo O; Pereiro X; Vecino E Proteomes; 2022 Jan; 10(1):. PubMed ID: 35076620 [TBL] [Abstract][Full Text] [Related]
17. Validation of hospital register-based diagnosis of Parkinson's disease. Wermuth L; Lassen CF; Himmerslev L; Olsen J; Ritz B Dan Med J; 2012 Mar; 59(3):A4391. PubMed ID: 22381086 [TBL] [Abstract][Full Text] [Related]